Latest Medical Devices News

Page 2 of 67
Solventum has raised its full-year adjusted earnings forecast after a third quarter shaped by the expected reversal of ERP-related advance orders. The healthcare technology company also completed its major system cutovers and reported strong growth in Advanced Wound Care.
Ada Torres
Ada Torres
6 Nov 2026
Edwards Lifesciences delivered stronger-than-expected third-quarter growth and lifted its full-year 2026 outlook, led by a sharp rise in mitral and tricuspid therapies. A US$220.2 million impairment charge remains a notable counterpoint to the upbeat operating performance.
Ada Torres
Ada Torres
5 Nov 2026
Insulet delivered a stronger-than-expected third quarter, with revenue up 19.2% and adjusted earnings per share rising nearly 60%. The diabetes-device maker also raised its operating-margin outlook and authorised a US$1 billion share repurchase programme.
Ada Torres
Ada Torres
4 Nov 2026
Zimmer Biomet lifted its full-year 2026 sales and adjusted earnings guidance after third-quarter constant-currency growth accelerated to 3.7%. The result was supported by strong hips, sports medicine and technology sales, although GAAP earnings fell and knees remained a weak spot.
Ada Torres
Ada Torres
4 Nov 2026
Marine Biomedical has secured US FDA 510(k) clearance for PearlBone, giving Orthocell a clearer path into bone regeneration through its 12% strategic stake and distribution rights. The commercial opportunity is advancing, but revenue, launch timing and definitive distribution arrangements remain undisclosed.
Ada Torres
Ada Torres
3 Nov 2026
Nexsen has secured ISO 13485 certification covering the design, development and manufacture of its StrepSure Group B Streptococcus diagnostic. The milestone strengthens the product’s regulatory and manufacturing platform, but does not yet amount to FDA or TGA approval.
Ada Torres
Ada Torres
2 Nov 2026
ResMed has delivered a stronger first quarter for fiscal 2027, with revenue up 6% to US$1.415 billion and net income rising 20% to US$418 million. The headline result was helped by a preliminary gain on the MatrixCare sale, while the core Sleep and Breathing Health business continued to expand.
Ada Torres
Ada Torres
2 Nov 2026
Osteopore reported record quarterly revenue of A$859,000 in Q3 CY26 as it added market access in Thailand and Saudi Arabia and completed its first customised Hainan implant. The regenerative implant maker remains cash-flow negative, with A$712,000 in cash and A$14 million still available under its convertible note facility.
Victor Sage
Victor Sage
30 Oct 2026
CONNEQT Health ended the September quarter with just A$501,000 in cash after a A$3.06 million operating outflow, equivalent to 0.16 quarters of funding at the reported burn rate. The company is pursuing R&D-backed debt, inventory finance and an equity raising as Pulse sales recover from an inventory disruption.
Victor Sage
Victor Sage
30 Oct 2026
Epiminder has enrolled its 100th patient in the DETECT US epilepsy study ahead of schedule, while maintaining A$65.1 million in cash and no borrowings. The company says those reserves can fund clinical development and commercialisation work well into 2028.
Victor Sage
Victor Sage
30 Oct 2026
OncoSil Medical enters FY27 with FDA approval for its cancer device, rising quarterly revenue and fresh institutional funding, but its U.S. opportunity still depends on reimbursement and a tightly controlled initial rollout. Cash rose to A$8.7 million after the capital raise, while operating cash use remained substantial.
Victor Sage
Victor Sage
30 Oct 2026
Tissue Repair has increased its US Phase III chronic wound trial to approximately 112 randomised patients while shifting focus towards an April 2027 FDA 510(k) submission. The company also reported $4.74 million in cash, Australian availability of all three TR Pro+ formats and a planned $1 million share buy-back.
Ada Torres
Ada Torres
29 Oct 2026

Browse the archive

Full archive